Scilex Holding Co (SCLXW) stock
SCLXWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLX
$0.04−0.00 (-1.53%)
Close on Oct 30, 2026Market cap $17.50MP/E –Yield –
Scilex operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Scilex's operating cash flow for the twelve months ending Jun 30, 2026 was -$17.09M, down 182.5% year over year. For fiscal 2025 it was $3.82M, down 80.3% from the year before. The highest annual figure on record is $19.35M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.82M | -80.3% |
| FY2024 | Dec 31, 2024 | $19.35M | – |
| FY2023 | Dec 31, 2023 | -$20.71M | – |
| FY2022 | Dec 31, 2022 | -$21.26M | – |
| FY2021 | Dec 31, 2021 | -$28.66M | – |
| FY2020 | Dec 31, 2020 | -$31.46M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.74M | -195.6% |
| Q1 FY2026 | Mar 31, 2026 | -$1.11M | -118.4% |
| Q4 FY2025 | Dec 31, 2025 | -$17.47M | -789.5% |
| Q3 FY2025 | Sep 30, 2025 | $8.23M | +61.0% |
| Q2 FY2025 | Jun 30, 2025 | $7.05M | +205.1% |
| Q1 FY2025 | Mar 31, 2025 | $6.01M | -36.0% |
| Q4 FY2024 | Dec 31, 2024 | $2.53M | – |
| Q3 FY2024 | Sep 30, 2024 | $5.11M | -13.3% |
| Q2 FY2024 | Jun 30, 2024 | $2.31M | – |
| Q1 FY2024 | Mar 31, 2024 | $9.39M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.39M | – |
| Q3 FY2023 | Sep 30, 2023 | $5.90M | +132.9% |
| Q2 FY2023 | Jun 30, 2023 | -$13.47M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.74M | – |
| Q4 FY2022 | Dec 31, 2022 | -$725.00K | – |
| Q3 FY2022 | Sep 30, 2022 | $2.53M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.34M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.73M | – |
| Q4 FY2021 | Dec 31, 2021 | -$27.97M | – |
| Q3 FY2021 | Sep 30, 2021 | -$141.98K | – |
| Q2 FY2021 | Jun 30, 2021 | -$551.63K | – |
| Q1 FY2021 | Mar 31, 2021 | -$494.33K | – |